A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home Treated Conditions Archive for category "Epilepsy"
formats

Cerbomed’s Non-Invasive Vagus Nerve Stimulator Poses Challenge to Implantable VNS Systems

Cerbomed GmbH, located in Erlangen, Germany, was founded in 2005 to develop transcutaneous Vagus Nerve Stimulation (t-VNS®) neuromodulation systems. Surgically accessing the Vagus Nerve is not trivial, and implanting a VNS system involving cuff electrodes is risky and recovery is lengthy.  Enter t-VNS, which is delivered non-invasively to the auricular branch of the vagus nerve (ABVN), making

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Cerbomed’s Non-Invasive Vagus Nerve Stimulator Poses Challenge to Implantable VNS Systems  comments 
formats

NeuroPace Receives FDA PMA Approval for for the RNS System to Treat Refractory Partial Epilepsy

NeuroPace is a privately-held company in Mountain View, CA. Their RNS® implantable stimulator, along with depth leads and cortical strip leads are designed for the treatment of medically refractory partial epilepsy. On November 14, 2013, NeuroPace has now received FDA pre-market approval for the NeuroPace RNS System as a treatment for adults with partial onset

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on NeuroPace Receives FDA PMA Approval for for the RNS System to Treat Refractory Partial Epilepsy  comments 
formats

Cyberonics Reports 12.4% Increase in VNS Sales for Fiscal Q1 2014

Net product sales increased 12.4% to $67.4 million in the first fiscal quarter ended July 26 for Cyberonics, Inc. of Houston, TX. Including license revenue, sales were up 14.2% overall, with Europe in particular contributing a strong performance. Diluted earnings per share were adjusted by $0.17 cents due to a litigation settlement. According to the

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Cyberonics Reports 12.4% Increase in VNS Sales for Fiscal Q1 2014  comments 
formats

NeuroPace Raises $18M of Planned $50M

NeuroPace is a privately-held company in Mountain View, CA. Their RNS® implantable stimulator, along with depth leads and cortical strip leads are designed for the treatment of medically refractory partial epilepsy. Unlike Cyberonics’ VNS IPGs, the RNS neurostimulator is designed to detect abnormal electrical activity in the brain and respond by delivering electrical stimulation to

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on NeuroPace Raises $18M of Planned $50M  comments 
formats

Neurotech’s ADNS-300 Rechargeable Vagus Nerve Stimulator IPG for Epilepsy

In June 2012 Neurotech s.a. (http://www.neurotech-int.eu), a Belgium based developer and manufacturer of neurostimulation devices, obtained the CE Mark for its ADNS-300 system for the treatment of refractory epilepsy. According to the press release: “Advens therapy” uses the ADNS-300 stimulator as a therapeutic option for those patients who are refractory to anti-epileptic drugs and are not

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Neurotech’s ADNS-300 Rechargeable Vagus Nerve Stimulator IPG for Epilepsy  comments 
formats

NeuroVista Publishes Study Results for their Implantable Seizure-Warning Device

  Seattle-based NeuroVista was founded in 2002 by Dr. Daniel DiLorenzo to develop an implantable device for the early detection of epileptic seizures.  The NeuroVista seizure advisory system is based on an implantable device that senses EEG irregularities that precede a seizure. Early warning allows patients to take medicine and find a safe place to

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on NeuroVista Publishes Study Results for their Implantable Seizure-Warning Device  comments 
formats

John Hopkins Researcher Develops New Early-Warning Seizures Detector with Low False-Positive Rate

Johns Hopkins’ Sridevi V. Sarma, an assistant professor of biomedical engineering, has devised new seizure detection software that, in early testing, significantly cuts the number of unneeded brain-stimulation therapy that an epilepsy patient would receive. According to Sarma, “These devices use algorithms—a series of mathematical steps—to figure out when to administer the treatment,” Sarma said. “They’re

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on John Hopkins Researcher Develops New Early-Warning Seizures Detector with Low False-Positive Rate  comments 
formats

Neuromed’s TIME Battery- and RF-Powered Totally Implantable Multichannel Spinal Cord Stimulator (ca. 1988)

Neuromed was formed in 1980 with an initial capitalization of $150,000 by Bill Borkan through money obtained when Borkan`s parents took out a second mortgage on their home. Borkan’s desire to help his sister, Jennie, a cerebral palsy patient, got him started in neurostimulation technology. In the next few years, Neuromed developed and marketed a

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Neuromed’s TIME Battery- and RF-Powered Totally Implantable Multichannel Spinal Cord Stimulator (ca. 1988)  comments 
formats

VeriMed’s Human-Implantable VeriChip Patient RFID

VeriMed’s VeriChip is the only RFID tag that has been cleared by FDA for human implant.  The concept behind the medical use of the VeriChip is that patients would have the tiny chip implanted just under the skin, in the back of the arm.  Each VeriMed microchip contains a unique identification number that emergency personnel may scan to

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
2 Comments  comments 
formats

NeuroVista’s Implantable EEG for Seizure Prediction

Seattle-based NeuroVista was founded in 2002 by Dr. Daniel DiLorenzo to develop an implantable device for the early detection of epileptic seizures. The NeuroVista seizure advisory system is based on an implantable device that senses EEG irregularities that precede a seizure. Early warning allows patients to take medicine and find a safe place to lie down. Although some

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
2 Comments  comments 
formats

CerebralRx FitNeS Vagus Nerve Stimulator for Epilepsy Treatment

In June 2011, Israeli neuromodulation systems developer BioControl Medical spun-off CerebralRx to market its FitNeS vagus nerve stimulation system for the treatment of refractory epilepsy. The FitNes system employs platform technology developed for the CardioFit® system for treating congestive heart failure (HF). CerebralRx spun out of BioControl Medical to expand the use of this technology outside of cardiology for the

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on CerebralRx FitNeS Vagus Nerve Stimulator for Epilepsy Treatment  comments 
formats

AIMD Companies Founded by Dr. Robert Fischell

Dr. Fischell received his BSME degree from Duke University and MS and Sc.D. degrees from the University of Maryland. Dr. Fischell was employed at the Johns Hopkins University where he was the Chief Engineer of the Space Department and worked on more than 50 spacecraft. His interests at Johns Hopkins then turned to the invention

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on AIMD Companies Founded by Dr. Robert Fischell  comments 
formats

AIMD Companies Founded by David R. Fischell, Ph.D.

Dr. David R. Fischell is a serial entrepreneur who has founded nine biomedical device companies in the last fifteen years. He is chairman of the Cornell University Biomedical Engineering Advisory Board, and a Fellow of the American Institute for Medical and Biological Engineering. After earning his Ph.D. in Applied Physics from Cornell University, Dr. Fischell

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on AIMD Companies Founded by David R. Fischell, Ph.D.  comments 
formats

NeuroPace’s Responsive Neurostimulator (RNS) for the Treatment of Epilepsy

NeuroPace is a privately-held company in Mountain View, CA.  Their RNS®  implantable stimulator, along with depth leads and cortical strip leads are designed for the treatment of medically refractory partial epilepsy. Unlike Cyberonics’ VNS IPGs, the RNS neurostimulator is designed to detect abnormal electrical activity in the brain and respond by delivering electrical stimulation to normalize brain activity

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
1 Comment  comments 
formats

Cyberonics’ Vagus Nerve Stimulators

Cyberonics was founded in Houston, TX in 1987 to develop an implantable device for the treatment of epilepsy.  In July 1997, The FDA approved the VNS Therapy System (formerly known as the NCP® NeuroCybernetic Prosthesis System) as an adjunctive epilepsy treatment for adults and children over 12 years of age with partial onset seizures refractory to

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Cyberonics’ Vagus Nerve Stimulators  comments